Abstract: The development of hepatocellular adenomas and -more rarely -carcinoma in the liver of patients with Glycogen Storage Disease type Ia (GSDIa) is a well-known complication of the disease. The pathophysiology of adenoma and carcinoma development in these patients is, however, hitherto largely unknown and is thought to be related to the metabolic control of the patient and/or the type of mutations in the G6PC gene. We report here on a very illustrative case of adenoma and carcinoma formation in a previously undiagnosed 42 year old male GSDIa patient (enzymatically and genetically proven). He had 2 episodes of mild hypoglycaemia in childhood, never required formal treatment, showed normal growth, only mild lactate increases after prolonged starvation. He was a long-distance runner for most of his adult life, without the need for more than normal carbohydrate intake before/during exertion. To gain a better view on the type of carcinoma formed in this patient, molecular studies were performed. We show here that in this patient with mild GSDIa without recurrent hypoglycaemic episodes adenoma and carcinoma formation still occurred and that malignant transformation of adenoma here is associated with CTNNB1 mutations and a typical mRNA profile of a beta-catenin activated lesion. 
ABSTRACT
The development of hepatocellular adenomas and -more rarely -carcinoma in the liver of patients with Glycogen Storage Disease type Ia (GSDIa) is a well-known complication of the disease. The pathophysiology of adenoma and carcinoma development in these patients is, however, hitherto largely unknown and is thought to be related to the metabolic control of the patient and/or the type of mutations in the G6PC gene. We report here on a very illustrative case of adenoma and carcinoma formation in a previously undiagnosed 42 year old male GSDIa patient (enzymatically and genetically proven). He had 2 episodes of mild hypoglycaemia in childhood, never required formal treatment, showed normal growth, only mild lactate increases after prolonged starvation. He was a long-distance runner for most of his adult life, without the need for more than normal carbohydrate intake before/during exertion. To gain a better view on the type of adenoma formed in this patient, molecular studies were performed. We show here that in this patient with mild GSDIa without recurrent hypoglycaemic episodes adenoma and carcinoma formation still occurred and that malignant transformation of adenoma here is associated with CTNNB1 mutations and a typical mRNA profile of a betacatenin activated lesion. GSDIa is a rare disorder, the molecular subtype of the typical adenomas in these patients is largely unknown. On the other hand, to be able to distinguish adenomas associated with malignant degeneration from the adenomas that will not turn malignant would be very worthwhile, to allow adequate selection of patients with GSDIa and adenomas for tumor resection or liver transplantation.
INTRODUCTION
Outside the context of GSDIa, it is becoming clear that adenomas that carry risk of malignant transformation are those carrying CTNNB1 mutations leading to an activation of ß-catenin, as opposed to the steatotic adenomas associated with HNF1A (Hepatocyte Nuclear factor 1 alpha) mutations and the inflammatory adenomas associated with IL6ST mutation, activating gp130.
3,4,5
MATERIALS AND METHODS

Patient
The patient signed a written informed consent form, approved by the local Ehical Committee (Leuven University Hospitals, Belgium).
Pathology
The resection specimen was received freshly and 8 biopsies taken from the lesion were snap-frozen in liquid nitrogen-cooled isopentane and stored at -80° for molecular evaluation. Standard histopathological examination and histochemical stains were performed as described previously. 8 Immunohistochemistry for beta-catenin and glutamine synthetase were performed according to a recently described protocol. Based on the radiological appearance, preference for adenomas was accepted. Carcino-embryonic antigen and alpha-fetoprotein were not determined.
There were no metastases within or outside of the liver, so the lesion was resected. The patient underwent a laparoscopic left hepatectomy with preservation of the middle hepatic vein. This was done in a standard fashion using the surgical aspirator (CUSA Excel, Integra Life Science Ltd, IDA Business and Technology Park, Ireland) with minimal blood loss provided by an unilateral vascular inflow exclusion before starting the resection.The pathology report of the resection specimen, is described below.
As a child, between 1 and 2 years of age, he experienced two episodes of syncope with suspected hypoglycaemia, during viral illness. The treatment consisted of oral intake of glucose. Clinically at that time there was hepatomegaly. A diagnosis of glycogenosis was suggested but not pursued, followed-up or treated accordingly. On the contrary, the patient was started on 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 a diet for celiac disease, which he was still following at the age of 42. He did not have a history of recurrent hypoglycaemia, nocturnal feeding, lactic acidosis. He had a late puberty and growth spurt but excellent catch-up growth to a total length of 170 cm (weight 61kg). He never experienced any problems with fasting or exertion, he on the contrary is a long-distance runner, running marathons without apparent need for extra carbohydrates before or during exertion. After a 12h fast, lactate was 4.49 mM (0.4-2.0; in fed state 1.22 mM on one occasion, 2.01 mM on another), glucose after 12h fast was 64 mg/dl (55-100), triglycerides 328 mg/dl (<=180), cholesterol 151 mg/dl (<=190), uric acid 5.0 mg/dL (3.5-7.2). Glycaemia measured at home in the mornings, in fasting state, or when feeling weak or hungry, were consistently normal. Creatine kinase and liver tests were normal. Echocardiography was normal as well as glomerular filtration rate. There was no proteinuria, there was no history of kidney stones. During work-up for a gastroenteritis episode, 7 years prior to his presentation with the current lesion, ultrasound showed a "somewhat enlarged, homogeneous liver" (no pictures stored for review).
Family history is unremarkable. There is no consanguinity. The patient has no children, has one healthy sister without similar complaints (routine biochemistry and liver ultrasound normal), both parents are alive and well around the age of 70.
At 1 year follow-up after the resection, the patient has resumed his work and sports without restraint. A malignant lesion measuring 23 cm is well outside Milan criteria for transplantation. The patient has declined the theoretical option of transplantation. Four-monthly control MRI of the liver shows no recurrence of HCC and stable size of the remaining adenomas, chest CT 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 shows no lung metastases.
Pathology report of the resection specimen
The partial hepatectomy specimen measured 19 x 13 x 9 cm and contained a multinodular tumor with a maximal diameter of 18 cm. The tumor had a lightbrown color in some areas and a yellow to greenish aspect in other areas.
Biopsies taken from the small rim of non-tumorous liver showed normal portal tracts and some fibrosis due to compression of the tumor. Very focally, there was some mixed steatosis. The periportal parenchyma contained numerous hepatocytes with a glycogenated nucleus (figure 1). Several hepatocytes also had a swollen, pale cytoplasm with wisps and small clumps of eosinophilic, giving the impression of so-called "plant-like" hepatocytes, which is suggestive of glycogen storage disease which is not of type 0 or 4 (figure 1). 11 Intense cytoplasmic hepatocytic positivity was not seen on the PAS-staining, most likely due to wash-out of glycogen during processing of the tissue.
The lesion consisted of several nodules of well differentiated hepatocellular carcinoma against a background of hepatocellular adenoma. The adenomatous areas consisted of sheets of non-steatotic hepatocytes organised as 1 to 2 cell thick plates separated by non-dilated sinusoids and traversed by some blood vessels. Reticulin surrounding these plates was preserved. Portal tracts, ductular reaction and inflammation were all absent.
The nuclei of the hepatocytes showed mild atypia: they were slightly irregular and contained chromatin clumps and a distinctive nucleolus. Based on these morphological features (figure 2a), the adenoma was suspected to be of the beta-catenin activated subtype. 
Diagnostic work-up for suspected glycogenosis
Glycogen phosphorylase kinase enzymatic activity on fresh red blood cells was normal. On snap-frozen liver biopsy, glycogen was 4.8% of wet liver weight (3.53+/-0.45), enzymatic activity of phosphorylase and hexose diphosphatase were normal, glucose-6-phosphatase activity was clearly reduced to 0.36 U/g (7.95 +/-0.51).
Mutation analysis of the G6PC gene revealed compound heterozygosity for p.Arg170X (c.508C>T) in exon 4 and p.Ala192Val (c.575C>T) in exon 5.
p.Arg170X has been described as a pathogenic mutation 10 , while p.Ala192Val
has not, but affects a phylogenetically highly conserved amino acid in a transmembrane domain of the protein and is thus predicted to be pathogenic.
Molecular studies of the HCC (8 biopsies)
Four random biopsies, taken from the large malignant lesion, showed the same mutation in CTNNB1: in-frame deletion Del7L-131L, while 4 other random biopsies showed another mutation in CTNNB1: in-frame deletion del21G-98M + ins21CC. No IL6ST or HNF1A mutations were found in any of the samples. We performed RT-PCR analysis testing the expression of 10 genes (LFABP1, UGT2B7, CRP, SAA, GLUL, GPR49, ANGPT1, ANGPT2, NTS, HAL) ( Table 1) . We found an mRNA expression profile typical of a ß-catenin activated adenoma in all samples, with overexpression of two genes targeted by ß-catenin (GLUL and GPR49) when compared to normal liver tissues (fold change T/N ranging from 3 to 374-fold, depending of the biopsies). Taken together, these results clearly demonstrate the presence of somatic CTNNB1 in-frame deletions activating ß-catenin in this lesion. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 
DISCUSSION
We report on a mild clinical presentation of GSDIa, where the diagnosis was missed early in life and the patient developed normally, without symptoms or complaints and without treatment or follow-up. Nevertheless, in adult age, the patient presented with multiple liver adenomas, one of which had developed into an HCC.
In the case presented here, the presence of hepatocytes with swollen and pale cytoplasm and with glycogenated nuclei in the tissue surrounding the resected hepatocellular carcinoma, together with a vague history of hypoglycaemia and hepatomegaly and an increased fasting lactate, set off the search for an underlying glycogenosis. The fact the patient has an enzymatically and genetically proven GSDIa and presented with adenomatosis and HCC in adult age, should prompt liver specialists and oncologists to look for GSDIa in patients presenting with adenomatosis and/or HCC, even when adult.
The presence of hepatocytes with swollen and pale cytoplasm is a well-known feature of GSD. 11 Although glycogenated nuclei in the periportal area are known to represent a disturbance of glycogen metabolism, as is seen in e.g.
NASH
12
, they have hitherto not been reported as a typical feature of GSD.
Therefore, it is possible that they are related to the atypical clinical presentation of this patient. If not, the presence of glycogenated nuclei would be an additional and easy feature to prompt pathologists and clinicians to explore underlying glycogenoses. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 The association of CTNNB1 mutations with malignant degeneration, is well known in sporadic liver adenoma. 3 Out of the 13 GSDIa-associated adenomas reported so far, 3 were CTNNB1 mutated. 3, 6, 7 Only one out of 13 was associated with an HCC and was CTNNB1 mutated. We describe another case here, where the resected malignant lesion carried different CTNNB1 mutations and an mRNA expression profile typical of a beta-catenin activation associated lesion ( Table 1 ).
The discrepancy between the rarity of nuclear positivity for beta-catenin and the diffuse positivity for its down-stream target gene glutamine synthetase in the lesion described here, is remarkable. This has also been observed recently by Bioulac-Sage et al. in 3 CTNNB1 mutated sporadic adenomas. 9 This case report suggests that glutamine synthetase is a more sensitive marker than beta-catenin itself, when screening for possible beta-catenin mutation is performed by immunohistochemistry. This has to be studied and confirmed in a larger series of adenomas.
Finally, several types of CTNNB1 mutations were present in one malignant lesion here and all 8 random biopsies carried CTNNB1 mutations. This suggests that at least two adenomas with distinct mutation types have undergone confluence, either before or after malignant transformation, but that all lesions giving rise to the malignant lesion were CTNNB1 mutated.
In a setting of organ shortage and in view of the risks associated with liver transplantation, it would be useful to gain a better insight into the type of adenomas in GSDIa patients that are likely to undergo malignant transformation and therefore would strengthen the case for liver transplantation. 13 By inference from what is know about sporadic adenomas, one would expect these to be the CTNNB1 mutated adenomas, i.e. glutamine synthetase positive or beta-catenin positive on immunohistochemistry. This is the second case of malignant transformation of a CTNNB1-mutated GSDIaassociated adenoma. If this association confirms itself in other patients, it would affect our treatment choices in these patients.
In conclusion, we describe a case of mild GSDIa, presenting with liver lesions in adult age. The HCC resected from this patient was CTNNB1 mutated, which confirms the premalignant nature of CTNNB1 mutated adenomas, also in GSDIa. Molecular studies for CTNNB1 mutations or routine immunohistochemistry for glutamine synthetase and beta-catenin, performed on punction biopsies taken from adenomas in GSDIa livers, could be useful to select patients with large and/or growing lesions for transplantation. Introduction -"because hepatocellular adenomas in these patients rarely require surgical intervention" There are a number of publications that document surgical intervention in patients with GSD I and adenomas.
A: some centers prefer to adopt a wait-and-see strategy with careful radiological follow-up of the lesions, even if adenomas exceed the generally accepted limit of 5 cm in size. The section was omitted.
Case Description -"As a child, between 1 and 2 years of age, he experienced two episodes of syncope with suspected hypoglycaemia, during viral illness. The treatment consisted of oral intake of glucose. Clinically at that time there was hepatomegaly. A diagnosis of glycogenosis was suggested but not proven. On the contrary, the patient was started on a diet for celiac disease, which he was still following at the age of 42." -We would argue that this was not a very mild case of GSD I. There were symptoms and signs of a GSD I diagnosis and "a diagnosis of glycogenosis was suggested" but because of lack of knowledge and work up, the diagnosis was missed.
A: this was changed accordingly: "A diagnosis of glycogenosis was suggested but not pursued, followed-up or treated accordingly."
-Did the patient have protienuria? What were the AFP and CEA values? Were these lab values done? Although we know they are not helpful in the adenoma setting, it is critical to know if in the HCC setting how they different from HCC in general population A: aFP and CEA were not determined, there was no proteinuria. This was added.
-"During work-up for a gastroenteritis episode, 7 years prior to his presentation with the current lesion, ultrasound showed a somewhat enlarged, homogeneous liver." -Was this ultrasound re-reviewed after the diagnosis of HCC 7 years later? Is it possible there were undetected adenomas that could be identified when re-reviewed based on the current diagnosis? There is a growing body of evidence that imaging modalities for adenomas requires MRI with contrast, thus this point needs to be highlighted in discussion and conclusions. Also, retrospective look may shed light on what may have been missed.
A: pictures were not available for review (ultrasound taken in emergency department setting, in a small rural hospital).
-"Four-monthly control MRI of the liver shows no recurrence of HCC and stable size of the remaining adenomas, chest CT shows no lung metastases." -Was this MRI with contrast? What were the size of the adenomas? Also, given the body of literature of recurrence of adenomas, the role of liver transplant in this setting needs discussion.
A: the requested data were added.
Discussion -Again -we argue that this was not a "very mild" case of GSD I. There were clinical symptoms and signs in the patient from an early age. The patient was missed because of a lack of work up and instead treated for celiac disease.
-not necessarily a "atypical clinical presentation" -maybe a milder clinical presentation. Current literature suggests there is a milder/less severe end of the GSD I phenotype. The patient had symptoms and in today's environment, the sypmtoms would have probably led to a diagnosis of GSD I. Also, the kidney involvenetpresence or absence of kidney stones, proteinuria and hypocitraturia are not mentione din teh clinical work up.
